Figure 1. Rate Ratios of the Monotherapy for the First and Subsequent Events Compared With Those of Combination Therapy and Mean Total Events per Treatment Group During the Trial Period.

A, Rivaroxaban monotherapy compared with combination therapy yielded 31% lower event rates for the first events. B, Rivaroxaban monotherapy compared with combination therapy yielded 54% lower event rates for the subsequent events. C, The mean cumulative function was estimated using the Nelson-Aalen nonparametric method. Total events included death from any cause, hemorrhagic and ischemic stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, and major bleeding, as defined according to the criteria of the International Society on Thrombosis and Hemostasis. Monotherapy yielded a significantly lower hazard of total events compared with combination therapy.